99 related articles for article (PubMed ID: 11243382)
21. The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11).
Valge-Archer V; Forster A; Rabbitts TH
Oncogene; 1998 Dec; 17(24):3199-202. PubMed ID: 9872335
[TBL] [Abstract][Full Text] [Related]
22. Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia.
Oram SH; Thoms J; Sive JI; Calero-Nieto FJ; Kinston SJ; Schütte J; Knezevic K; Lock RB; Pimanda JE; Göttgens B
Leukemia; 2013 Jun; 27(6):1348-57. PubMed ID: 23302769
[TBL] [Abstract][Full Text] [Related]
23. Transcription factors of the bHLH and LIM families: synergistic mediators of T cell acute leukemia?
Baer R; Hwang LY; Bash RO
Curr Top Microbiol Immunol; 1997; 220():55-65. PubMed ID: 9103675
[No Abstract] [Full Text] [Related]
24. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.
Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932
[TBL] [Abstract][Full Text] [Related]
25. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.
Visvader JE; Mao X; Fujiwara Y; Hahm K; Orkin SH
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13707-12. PubMed ID: 9391090
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase.
Allay E; Reese JS; McGuire EA; Koç ON; Sedransk N; Gerson SL
Oncogene; 1997 Oct; 15(17):2127-32. PubMed ID: 9366529
[TBL] [Abstract][Full Text] [Related]
27. Deregulated expression of TCL1 causes T cell leukemia in mice.
Virgilio L; Lazzeri C; Bichi R; Nibu K; Narducci MG; Russo G; Rothstein JL; Croce CM
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3885-9. PubMed ID: 9520462
[TBL] [Abstract][Full Text] [Related]
28. The SCL gene product is regulated by and differentially regulates cytokine responses during myeloid leukemic cell differentiation.
Tanigawa T; Elwood N; Metcalf D; Cary D; DeLuca E; Nicola NA; Begley CG
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7864-8. PubMed ID: 8356096
[TBL] [Abstract][Full Text] [Related]
29. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia.
Grutz G; Forster A; Rabbitts TH
Oncogene; 1998 Nov; 17(21):2799-803. PubMed ID: 9840944
[TBL] [Abstract][Full Text] [Related]
30. High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.
Gerby B; Veiga DF; Krosl J; Nourreddine S; Ouellette J; Haman A; Lavoie G; Fares I; Tremblay M; Litalien V; Ottoni E; Kosic M; Geoffrion D; Ryan J; Maddox PS; Chagraoui J; Marinier A; Hébert J; Sauvageau G; Kwok BH; Roux PP; Hoang T
J Clin Invest; 2016 Dec; 126(12):4569-4584. PubMed ID: 27797342
[TBL] [Abstract][Full Text] [Related]
31. scl, a gene frequently activated in human T cell leukaemia, does not induce lymphomas in transgenic mice.
Robb L; Rasko JE; Bath ML; Strasser A; Begley CG
Oncogene; 1995 Jan; 10(1):205-9. PubMed ID: 7824274
[TBL] [Abstract][Full Text] [Related]
32. Absence of SCL mutations in myeloid malignancies.
Delabesse E; Li J; Schnittger S; Hiddemann W; Green AR
Br J Haematol; 2003 Feb; 120(3):482-3. PubMed ID: 12580964
[TBL] [Abstract][Full Text] [Related]
33. SCL/Tal-1 expression in T-acute lymphoblastic leukemia: an immunohistochemical and genotypic study.
Chetty R; Pulford K; Jones M; Mathieu-Mahul D; Close P; Hussein S; Pallesen G; Ralfkiaer E; Stein H; Gatter K
Hum Pathol; 1995 Sep; 26(9):994-8. PubMed ID: 7672800
[TBL] [Abstract][Full Text] [Related]
34. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice.
Curtis DJ; Robb L; Strasser A; Begley CG
Oncogene; 1997 Dec; 15(24):2975-83. PubMed ID: 9416841
[TBL] [Abstract][Full Text] [Related]
35. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.
Marculescu R; Le T; Simon P; Jaeger U; Nadel B
J Exp Med; 2002 Jan; 195(1):85-98. PubMed ID: 11781368
[TBL] [Abstract][Full Text] [Related]
36. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
37. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice.
Neale GA; Rehg JE; Goorha RM
Leukemia; 1997 Apr; 11 Suppl 3():289-90. PubMed ID: 9209368
[TBL] [Abstract][Full Text] [Related]
38. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.
Lin YW; Nichols RA; Letterio JJ; Aplan PD
Blood; 2006 Mar; 107(6):2540-3. PubMed ID: 16282337
[TBL] [Abstract][Full Text] [Related]
39. Expression of the proto-oncogene rhombotin-2 is identical to the acute phase response protein metallothionein, suggesting multiple functions.
Neale GA; Mao S; Parham DM; Murti KG; Goorha RM
Cell Growth Differ; 1995 May; 6(5):587-96. PubMed ID: 7544155
[TBL] [Abstract][Full Text] [Related]
40. The basic helix-loop-helix transcription factor TAL1/SCL inhibits the expression of the p16INK4A and pTalpha genes.
Hansson A; Manetopoulos C; Jönsson JI; Axelson H
Biochem Biophys Res Commun; 2003 Dec; 312(4):1073-81. PubMed ID: 14651981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
